MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/ccd.29276

Медицинская библиотека · Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2020

Preprocedural anemia in females undergoing transcatheter aortic valve implantation: Insights from the WIN-TAVI registry.

Nicolas Johny, Claessen Bimmer E, Cao Davide, Sartori Samantha, Baber Usman, Power David, Chiarito Mauro, Goel Ridhima, Roumeliotis Anastasios, Chandiramani Rishi, Chen Siyan, Chandrasekhar Jaya, Tchetche Didier, Petronio Anna Sonia, Mehilli Julinda, Lefèvre Thierry, Presbitero Patrizia, Capranzano Piera, Iadanza Alessandro, Sardella Gennaro, Van Mieghem Nicolas M, Meliga Emanuele, Dumonteil Nicolas, Fraccaro Chiara, Trabattoni Daniela, Mikhail Ghada, Ferrer-Gracia Maria-Cruz, Naber Christoph, Sharma Samin, Morice Marie-Claude, Dangas George D, Chieffo Alaide, Mehran Roxana

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVES

To assess the impact of anemia on clinical outcomes in female patients enrolled in the Women's InterNational transcatheter aortic valve implantation (WIN-TAVI) registry.

BACKGROUND

Anemia is highly prevalent among females who constitute half of TAVI candidates, yet, its clinical significance remains poorly investigated.

METHODS

Patients were divided into three groups according to preprocedural hemoglobin (Hb) level: (1) no anemia (Hb ≥12 g/dl), (2) mild-to-moderate anemia (10 ≤ Hb <12 g/dl), and (3) severe anemia (Hb <10 g/dl). The primary outcome was the occurrence of Valve Academic Research Consortium (VARC)-2 efficacy endpoint, a composite of mortality, stroke, myocardial infarction (MI), hospitalization for valve-related symptoms or heart failure or valve-related dysfunction at 1-year follow-up.

RESULTS

Hemoglobin level was available in 877 (86.1%) patients: 412 (47.0%) had no anemia, 363 (41.4%) had mild-to-moderate anemia, and 102 (11.6%) had severe anemia. The latter group had a higher prevalence of cardiovascular risk factors. Compared with patients without anemia, severe anemia was associated with a greater risk of VARC-2 efficacy endpoint (adj HR 1.71, 95% CI: 1.02-2.87, p = .04), all-cause death (adj HR 2.36, 95% CI: 1.31-4.26, p = .004) and a composite of death, MI or stroke (adj HR 1.88, 95% CI: 1.10-3.22, p = .02) at 1 year. Moreover, an increased risk of late mortality (adj HR 1.15, 95% CI: 1.02-1.30, p = .03) was observed with every 1 g/dl decrease in hemoglobin level.

CONCLUSION

Severe anemia in females undergoing TAVI was independently associated with increased rates of VARC-2 efficacy endpoint and mortality at 1 year.

Для цитирования: Nicolas Johny, Claessen Bimmer E, Cao Davide, Sartori Samantha, Baber Usman, Power David, Chiarito Mauro, Goel Ridhima, Roumeliotis Anastasios, Chandiramani Rishi, Chen Siyan, Chandrasekhar Jaya, Tchetche Didier, Petronio Anna Sonia, Mehilli Julinda, Lefèvre Thierry, Presbitero Patrizia, Capranzano Piera, Iadanza Alessandro, Sardella Gennaro, Van Mieghem Nicolas M, Meliga Emanuele, Dumonteil Nicolas, Fraccaro Chiara, Trabattoni Daniela, Mikhail Ghada, Ferrer-Gracia Maria-Cruz, Naber Christoph, Sharma Samin, Morice Marie-Claude, Dangas George D, Chieffo Alaide, Mehran Roxana. Preprocedural anemia in females undergoing transcatheter aortic valve implantation: Insights from the WIN-TAVI registry.. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 2020. DOI: 10.1002/ccd.29276.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.